Jinhua Qinggan granule, a Chinese herbal medicine against COVID‑19, induces rapid changes in the neutrophil/lymphocyte ratio and plasma levels of IL‑6 and IFN‑γ: An open‑label, single‑arm pilot study

Kageyama,Yasunari; Aida,Koichi; Kawauchi,Kimihiko; Morimoto,Masafumi; Ebisui,Tomoka; Akiyama,Tetsu; Nakamura,Tsutomu

doi:10.3892/wasj.2021.137

Jinhua Qinggan granule, a Chinese herbal medicine against COVID‑19, induces rapid changes in the neutrophil/lymphocyte ratio and plasma levels of IL‑6 and IFN‑γ: An open‑label, single‑arm pilot study

Authors:
- Yasunari Kageyama
- Koichi Aida
- Kimihiko Kawauchi
- Masafumi Morimoto
- Tomoka Ebisui
- Tetsu Akiyama
- Tsutomu Nakamura
View Affiliations

Affiliations: Takanawa Clinic, Minato‑ku, Tokyo 108‑0074, Japan, Laboratory of Molecular and Genetic Information, Institute for Quantitative Biosciences, University of Tokyo, Bunkyo‑ku, Tokyo 113‑0032, Japan
Published online on: November 16, 2021 https://doi.org/10.3892/wasj.2021.137
Article Number: 2
Copyright: © Kageyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Traditional Chinese herbal medicine has provided clinical benefits to patients infected with coronavirus 2019 (COVID‑19) in China. Jinhua Qinggan granule (JHQGG) is a Chinese multi‑herbal formula previously developed for the treatment of H1N1 influenza and has been encouraged for use in patients with clinically suspected COVID‑19 infection. However, the immunopharmacological mechanism for the efficacy of JHQGG has not yet been confirmed. To obtain insight into this issue, the present study examined the acute effects of JHQGG ingestion on hematological and immunological parameters using uninfected individuals as subjects. For this purpose, 18 healthy volunteers were enrolled, all of whom tested negative for prior and current severe acute respiratory syndrome coronavirus 2 infection. Peripheral blood samples were collected 1 h after a single oral JHQGG administration and subjected to hematological, biochemical and cytokine tests. JHQGG rapidly induced a significant decrease in the plasma level of interleukin (IL)‑6 (P=0.00309) and an increase in the plasma level of interferon (IFN)‑γ (P=0.0268). A decrease in IL‑6 and an increase in IFN‑γ levels were observed in 14 (77.8%) and 13 (72.2%) subjects, respectively. Notably, JHQGG significantly decreased the proportion of neutrophils (P=0.00561) and increased that of lymphocytes (P=0.00485); accordingly, the neutrophil/lymphocyte ratio (NLR) was significantly reduced by JHQGG (P=0.00649). These findings suggest that the clinical benefits of the use of JHQGG against COVID‑19 are, at least in part, associated with its rapid modulatory effects on IL‑6, IFN‑γ and NLR. Considering that IL‑6 and NLR are critical biomarkers for severe COVID‑19 infection, JHQGG may thus be suitable not only for suppressing disease onset in suspected and asymptomatic cases, but also for preventing disease progression in patients with mild to severe infection. The present open‑label, single‑arm study has been prospectively registered on the University Hospital Medical Information Network‑Clinical Trials Registry (UMIN‑CTR) under the trial no. UMIN000040407 on May 15, 2020.

View Figures

View References

1	Yang Y, Islam MS, Wang J, Li Y and Chen X: Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective. Int J Biol Sci. 16:1708–1717. 2020.PubMed/NCBI View Article : Google Scholar
2	Luo H, Gao Y, Zou J, Zhang S, Chen H, Liu Q, Tan D, Han Y, Zhao Y and Wang S: Reflections on treatment of COVID-19 with traditional Chinese medicine. Chin Med. 15(94)2020.PubMed/NCBI View Article : Google Scholar
3	Zhao Z, Li Y, Zhou L, Zhou X, Xie B, Zhang W and Sun J: Prevention and treatment of COVID-19 using Traditional Chinese Medicine: A review. Phytomedicine. 85(153308)2021.PubMed/NCBI View Article : Google Scholar
4	Wei PF: Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7). Chin Med J (Engl). 133:1087–1095. 2020.PubMed/NCBI View Article : Google Scholar
5	Tao Z, Yang Y, Shi W, Xue M, Yang W, Song Z, Yao C, Yin J, Shi D, Zhang Y, et al: Complementary and alternative medicine is expected to make greater contribution in controlling the prevalence of influenza. Biosci Trends. 7:253–256. 2013.PubMed/NCBI
6	Li GQ, Zhao J, Tu ZT, Li JB, Liu QQ, Shi LQ, Miao Q, Yuan HQ, Liu XQ, Long YY, et al: Treating influenza patients of wind-heat affecting Fei syndrome by jinhua qinggan granule: A double-blinded randomized control trial. Zhongguo Zhong Xi Yi Jie He Za Zhi. 33:1631–1635. 2013.PubMed/NCBI(In Chinese).
7	Wu L, Chen Y, Ma Y, Yang Z, Yang N, Deng W, Chen Y, Sun Y, Li Y and Lin L: Clinical practice guideline on treating influenza in adult patients with Chinese patent medicines. Pharmacol Res. 160(105101)2020.PubMed/NCBI View Article : Google Scholar
8	Ang L, Song E, Lee HW and Lee MS: Herbal medicine for the treatment of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of randomized controlled trials. J Clin Med. 9(1583)2020.PubMed/NCBI View Article : Google Scholar
9	Liu Z, Li X, Gou C, Li L, Luo X, Zhang C, Zhang Y, Zhang J, Jin A, Li H, et al: Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients. J Tradit Chin Med. 40:467–472. 2020.PubMed/NCBI View Article : Google Scholar
10	Wang J and Qi F: Traditional Chinese medicine to treat COVID-19: The importance of evidence-based research. Drug Discov Ther. 14:149–150. 2020.PubMed/NCBI View Article : Google Scholar
11	Liu M, Gao Y, Yuan Y, Yang K, Shi S, Zhang J and Tian J: Efficacy and safety of integrated traditional Chinese and Western medicine for corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. Pharmacol Res. 158(104896)2020.PubMed/NCBI View Article : Google Scholar
12	Niu WH, Wu F, Cao WY, Wu ZG, Chao YC and Liang C: Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6. Biosci Rep: Jan 29, 2021 (Epub ahead of print). doi: 10.1042/BSR20202583.
13	Niu W, Wu F, Cui H, Cao W, Chao Y, Wu Z, Fan M and Liang C: Network pharmacology analysis to identify phytochemicals in traditional Chinese medicines that may regulate ACE2 for the treatment of COVID-19. Evid Based Complement Alternat Med. 2020(7493281)2020.PubMed/NCBI View Article : Google Scholar
14	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
15	Faul F, Erdfelder E, Lang AG and Buchner A: G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 39:175–191. 2007.PubMed/NCBI View Article : Google Scholar
16	Kageyama Y, Aida K, Kawauchi K, Morimoto M, Ebisui T, Akiyama T and Nakamura T: Qingfei Paidu decoction, a Chinese herbal medicine against COVID 19, elevates the blood levels of pro inflammatory cytokines: An open label, single arm pilot study. World Acad Sci J. 3(25)2021.
17	Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L, et al: Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 55(102763)2020.PubMed/NCBI View Article : Google Scholar
18	Li X, Liu C, Mao Z, Xiao M, Wang L, Qi S and Zhou F: Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: A systematic review and meta-analysis. Crit Care. 24(647)2020.PubMed/NCBI View Article : Google Scholar
19	Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, Dassler-Plenker J, Guerci P, Huynh C, Knight JS, et al: Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 217(e20200652)2020.PubMed/NCBI View Article : Google Scholar
20	Peiró T, Patel DF, Akthar S, Gregory LG, Pyle CJ, Harker JA, Birrell MA, Lloyd CM and Snelgrove RJ: Neutrophils drive alveolar macrophage IL-1β release during respiratory viral infection. Thorax. 73:546–556. 2018.PubMed/NCBI View Article : Google Scholar
21	Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair C, Weber A, Barnes BJ, Egeblad M, et al: Neutrophil extracellular traps in COVID-19. JCI Insight. 5(e138999)2020.PubMed/NCBI View Article : Google Scholar
22	Laforge M, Elbim C, Frère C, Hémadi M, Massaad C, Nuss P, Benoliel JJ and Becker C: Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol. 20:515–516. 2020.PubMed/NCBI View Article : Google Scholar
23	Batiha GE, Beshbishy AM, Ikram M, Mulla ZS, El-Hack ME, Taha AE, Algammal AM and Elewa YH: The pharmacological activity, biochemical properties, and pharmacokinetics of the major natural polyphenolic flavonoid: Quercetin. Foods. 9(374)2020.PubMed/NCBI View Article : Google Scholar
24	Erlund I, Kosonen T, Alfthan G, Mäenpää J, Perttunen K, Kenraali J, Parantainen J and Aro A: Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol. 56:545–553. 2000.PubMed/NCBI View Article : Google Scholar
25	Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H and Veit M: Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol. 41:492–499. 2001.PubMed/NCBI View Article : Google Scholar
26	Lee J and Mitchell AE: Pharmacokinetics of quercetin absorption from apples and onions in healthy humans. J Agric Food Chem. 60:3874–3881. 2012.PubMed/NCBI View Article : Google Scholar
27	Wang Z, Zeng M, Wang Z, Qin F, Chen J and He Z: Dietary luteolin: A narrative review focusing on its pharmacokinetic properties and effects on glycolipid metabolism. J Agric Food Chem. 69:1441–1454. 2021.PubMed/NCBI View Article : Google Scholar
28	Chen T, Li LP, Lu XY, Jiang HD and Zeng S: Absorption and excretion of luteolin and apigenin in rats after oral administration of Chrysanthemum morifolium extract. J Agric Food Chem. 55:273–277. 2007.PubMed/NCBI View Article : Google Scholar
29	Yasuda MT, Fujita K, Hosoya T, Imai S and Shimoi K: Absorption and metabolism of luteolin and its glycosides from the extract of chrysanthemum morifolium flowers in rats and Caco-2 cells. J Agric Food Chem. 63:7693–7699. 2015.PubMed/NCBI View Article : Google Scholar
30	Cao X: COVID-19: Immunopathology and its implications for therapy. Nat Rev Immunol. 20:269–270. 2020.PubMed/NCBI View Article : Google Scholar
31	Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, Damoraki G, Gkavogianni T, Adami ME, Katsaounou P, et al: Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 27:992–1000.e3. 2020.PubMed/NCBI View Article : Google Scholar
32	Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, Jia X, Wu M, Shi B, Xu S, et al: Viral and host factors related to the clinical outcome of COVID-19. Nature. 583:437–440. 2020.PubMed/NCBI View Article : Google Scholar
33	Tleyjeh IM, Kashour Z, Damlaj M, Riaz M, Tlayjeh H, Altannir M, Altannir Y, Al-Tannir M, Tleyjeh R, Hassett L, et al: Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic review and meta-analysis. Clin Microbiol Infect. 27:215–227. 2021.PubMed/NCBI View Article : Google Scholar
34	Hoffmann HH, Schneider WM and Rice CM: Interferons and viruses: An evolutionary arms race of molecular interactions. Trends Immunol. 36:124–138. 2015.PubMed/NCBI View Article : Google Scholar
35	Kang S, Brown HM and Hwang S: Direct antiviral mechanisms of interferon-γ. Immune Netw. 18(e33)2018.PubMed/NCBI View Article : Google Scholar
36	Kim MH, Salloum S, Wang JY, Wong LP, Regan J, Lefteri K, Manickas-Hill Z, Gao C, Li JZ, Sadreyev RI, et al: MGH COVID-19 Collection and Processing Team: Type I, II, and III interferon signatures correspond to coronavirus disease 2019 severity. J Infect Dis. 224:777–782. 2021.PubMed/NCBI View Article : Google Scholar
37	Ruetsch C, Brglez V, Crémoni M, Zorzi K, Fernandez C, Boyer-Suavet S, Benzaken S, Demonchy E, Risso K, Courjon J, et al: Functional exhaustion of type I and II interferons production in severe COVID-19 patients. Front Med (Lausanne). 7(603961)2021.PubMed/NCBI View Article : Google Scholar
38	Hu ZJ, Xu J, Yin JM, Li L, Hou W, Zhang LL, Zhou Z, Yu YZ, Li HJ, Feng YM, et al: Lower circulating interferon-γ is a risk factor for lung fibrosis in COVID-19 patients. Front Immunol. 11(585647)2020.PubMed/NCBI View Article : Google Scholar
39	Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, et al: Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 130:2620–2629. 2020.PubMed/NCBI View Article : Google Scholar
40	Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, Mencarini J, Caporale R, Peruzzi B, Antonelli A, et al: Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 130:4694–4703. 2020.PubMed/NCBI View Article : Google Scholar
41	Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y and Tian Z: Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 17:533–535. 2020.PubMed/NCBI View Article : Google Scholar
42	Kyuwa S and Sugiura Y: Role of cytotoxic T lymphocytes and interferon-γ in coronavirus infection: Lessons from murine coronavirus infections in mice. J Vet Med Sci. 82:1410–1414. 2020.PubMed/NCBI View Article : Google Scholar
43	Lagunas-Rangel FA and Chávez-Valencia V: High IL-6/IFN-γ ratio could be associated with severe disease in COVID-19 patients. J Med Virol. 92:1789–1790. 2020.PubMed/NCBI View Article : Google Scholar
44	Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodríguez Y, Gallo JE, Salazar-Uribe JC, Santander MJ, Cala MP, Zapata W, Zapata MI, et al: CP-COVID-19 group: COVID-19 convalescent plasma composition and immunological effects in severe patients. J Autoimmun. 118(102598)2021.PubMed/NCBI View Article : Google Scholar